Cart
sales@molnova.com
JNJ-42041935
CAS No. 1193383-09-3
JNJ-42041935( JNJ42041935 )
Catalog No. M10673 CAS No. 1193383-09-3
JNJ-42041935 is a potent, selective, 2-OG-competitive, reversible inhibitor of HIF-PHD.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 72 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 200 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 537 | In Stock |
|
| 500MG | 1134 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNJ-42041935
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNJ-42041935 is a potent, selective, 2-OG-competitive, reversible inhibitor of HIF-PHD.
-
DescriptionJNJ-42041935 is a potent, selective, 2-OG-competitive, reversible inhibitor of HIF-PHD with pKi of 7.91, 7.29 and 7.65 for PHD1, PHD2 and PHD3, respectively; shows highly selectivity for PHD relative to FIH (pIC50=4.0); JNJ-42041935 is approximately equipotent in the HIF-1α accumulation and erythropoietin secretion assays in Hep3B cells as DMOG and 3,4-EDHB; reverses inflammation-induced anemia at dose of 100 μmol/kg, whereas erythropoietin has no effect.
-
In Vitro——
-
In Vivo——
-
SynonymsJNJ42041935
-
PathwayAngiogenesis
-
TargetHIF/HIF Prolyl-hydroxylase
-
RecptorPHD1|PHD2|PHD3
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number1193383-09-3
-
Formula Weight346.6493
-
Molecular FormulaC12H6ClF3N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 36 mg/mL
-
SMILESClC1=CC2=C(NC(N3C=C(C(O)=O)C=N3)=N2)C=C1OC(F)(F)F
-
Chemical Name1H-Pyrazole-4-carboxylic acid, 1-[6-chloro-5-(trifluoromethoxy)-1H-benzimidazol-2-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Barrett TD, et al. Mol Pharmacol. 2011 Jun;79(6):910-20.
molnova catalog
related products
-
TAT-cyclo-CLLFVY
Selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
-
SYP-5
A novel potent HIF-1 inhibitor that inhibits hypoxia-induced upregulation of HIF-1.
-
Oligomycin
Oligomycin is an antifungal antibiotic that is an inhibitor of H+-ATP synthetase.
